TME Pharma


The press releases published by TME Pharma (formerly NOXXON Pharma) and contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. TME Pharma disavows any obligation to update the information contained in such press releases after the date of their issuance.

Filter: NOX-A12 (olaptesed)NOX-E36 (emapticap) | all

DateTitleDownload

2024, March 05
08:00 a.m.
TME Pharma announces FDA clearance of Investigational New Drug (IND) application for NOX-A12 Phase 2 trial in brain cancer

2024, February 23
08:00 a.m.
TME Pharma provides results of final exercise of Warrants Y: Additional €854k raised and extension of cash runway from May into July 2024

2024, February 09
08:00 a.m.
TME Pharma announces the end of the convertible debt program with the successful €1.48 million financing intended for buyback of all outstanding convertible debt

2024, February 02
08:00 a.m.
TME Pharma announces final median overall survival data reaching 19.9 months for NOX-A12 combination regimen in GLORIA brain cancer trial and survival rate 10-fold greater than standard of care

2024, January 31
06:00 p.m.
Half-yearly report on the liquidity contract with Invest Securities

2024, January 23
06:00 p.m.
TME Pharma provides update on number of outstanding shares and warrants following first Warrant Y exercise period

2024, January 09
06:00 p.m.
TME Pharma announces successful advice meeting with US Food and Drug Administration on NOX-A12 development in brain cancer

2023, December 20
08:00 a.m.
TME Pharma announces further improvement in median overall survival at 19 months follow-up in GLORIA brain cancer trial

2023, December 14
08:00 a.m.
TME Pharma announces results of successful capital increase with preferential subscription rights for €2.7 million

2023, November 28
08:00 a.m.
TME Pharma announces the initiation of the listing of preferential subscription rights for fully guaranteed €2.7 million capital increase

2023, November 24
06:00 p.m.
TME Pharma launches fully guaranteed €2.7 million preferential rights issue with warrants attached combined with buyback of convertible debt

2023, November 18
08:00 a.m.
TME Pharma announces additional data from NOX-A12 combination regimen in brain cancer presented at SNO 2023 Annual Meeting

2023, October 27
06:00 p.m.
TME Pharma reports H1 2023 financial results and provides business update

2023, October 20
08:00 a.m.
TME Pharma announces further improvement in overall survival at 18 months to 67% for NOX-A12 combination regimen in brain cancer

2023, October 17
07:00 p.m.
TME Pharma reports on end of six-month lock-up period of shares and convertible bonds following the April 2023 transaction

2023, October 16
08:00 a.m.
TME Pharma announces publication of ESMO Congress 2023 abstract on the ongoing NOX-A12 GLORIA Phase 1/2 trial in glioblastoma

2023, October 10
08:00 a.m.
TME Pharma provides positive update on 18-month survival for NOX-A12 combination regimen in brain cancer and provides strategic update including decision to engage with US FDA

2023, September 22
08:00 a.m.
TME Pharma announces selection of two clinical abstracts on the ongoing NOX-A12 GLORIA Phase 1/2 trial in glioblastoma for presentation at ESMO 2023 congress and SNO 2023 Annual Meeting

2023, September 13
08:00 a.m.
NOX-A12 combination regimen with bevacizumab: 17-month survival rate exceeds all relevant competitor treatments against most severe form of adult brain cancer

2023, July 20
06:00 p.m.
Half-yearly report on the liquidity contract with invest securities

2023, July 13
08:00 a.m.
TME Pharma provides positive data update on best response to therapy with first complete response in GLORIA trial in glioblastoma, bringing 50% of patients in expansion arm to complete or near-complete response

2023, June 30
06:00 p.m.
TME Pharma provides results of its 2023 annual general meeting of shareholders and announces the resumption of the liquidity contract

2023, June 28
08:00 a.m.
TME Pharma announces positive 15-month survival data from GLORIA expansion arm evaluating NOX-A12 in combination with radiotherapy and bevacizumab in glioblastoma

2023, June 15
06:00 p.m.
TME Pharma receives Investigational New Drug (IND) approval for NOX-A12 from the US FDA

2023, May 30
08:00 a.m.
TME Pharma announces convocation of the 2023 annual general meeting of shareholders

2023, May 26
08:00 a.m.
TME Pharma announces publication of ASCO 2023 abstract disclosing new biomarker data from NOX-A12 GLORIA Phase 1/2 trial in glioblastoma

2023, May 25
06:00 p.m.
TME Pharma provides positive clinical update and 14-month survival data from GLORIA expansion arm evaluating NOX-A12 in combination with radiotherapy and bevacizumab in glioblastoma

2023, April 27
08:00 a.m.
TME Pharma announces new data from NOX-A12 GLORIA Phase 1/2 study in glioblastoma to be presented at ASCO annual meeting in June 2023

2023, April 24
06:00 p.m.
TME Pharma publishes audited Annual Report 2022

2023, April 18
08:00 p.m.
TME Pharma announces successful €2 million financing and the end of the convertible bond program with a lock-up of new shares and lock-up of bond conversions extending financial runway into December 2023

2023, April 18
06:00 p.m.
TME Pharma publishes unaudited financial results for fiscal year 2022

2023, March 29
08:45 a.m.
TME Pharma announces temporary suspension of liquidity contract with Invest Securities

2023, March 27
08:00 a.m.
TME Pharma announces 83% of glioblastoma patients still alive after 12 months on study (median) in GLORIA expansion arm evaluating NOX-A12 in combination with radiotherapy and bevacizumab

2023, February 24
08:00 a.m.
TME Pharma CEO message

2023, January 30
06:00 p.m.
TME Pharma announces results of the extraordinary general meeting of shareholders

2023, January 23
08:00 a.m.
TME Pharma provides clinical update on the GLORIA expansion arm testing NOX-A12 in combination with radiotherapy and bevacizumab in patients with glioblastoma

2023, January 20
06:00 p.m.
Half-yearly report on the liquidity contract with Invest Securities

2022, December 30
06:00 p.m.
TME Pharma announces convocation of an extraordinary general meeting of shareholders

2022, November 28
06:00 p.m.
TME Pharma announces the resignation of its Chief Financial Officer Bryan Jennings

2022, November 19
01:30 a.m.
Positive updated interim results from NOX-A12 GLORIA Phase 1/2 in brain cancer presented at the Society for Neuro-Oncology 2022 Annual Meeting

2022, November 14
08:00 a.m.
TME Pharma to host key opinion leader webinar

2022, November 11
01:00 p.m.
TME Pharma announces publication of abstract disclosing positive interim results from bevacizumab expansion arm of NOX-A12 GLORIA Phase 1/2 brain cancer clinical trial additional and updated data to be presented during SNO 2022 Annual Meeting on Nov 18, 2022

2022, October 26
07:00 p.m.
TME Pharma reports H1 2022 financial results and provides business update

2022, September 20
06:00 p.m.
TME Pharma announces upcoming presentation at the Society for Neuro-Oncology Annual Meeting 2022

2022, August 26
08:00 a.m.
Safety confirmed of NOX-A12 and pembrolizumab combination in GLORIA Phase 1/2 brain cancer study

2022, August 03
08:00 a.m.
TME Pharma announces enrollment of first patient in pembrolizumab expansion arm of NOX-A12 GLORIA Phase 1/2 brain cancer clinical trial

2022, July 27
07:00 p.m.
TME Pharma announces completion of share consolidation

2022, July 15
06:00 p.m.
TME Pharma announces €3.24 million financing under agreement with Atlas

2022, July 15
08:00 a.m.
NOXXON Pharma announces name change to “TME Pharma” and new trading symbol

2022, July 12
06:00 p.m.
Half-yearly report on the liquidity contract with Invest Securities

2022, July 12
06:00 p.m.
NOXXON announces changes to its supervisory board

2022, June 29
06:00 p.m.
NOXXON provides results of its 2022 annual general meeting of shareholders

2022, June 23
08:00 a.m.
NOXXON announces updated development strategy following strong clinical benefit observed with NOX-A12 in combination with radiotherapy and bevacizumab in brain cancer

2022, June 23
08:00 a.m.
NOXXON announces corporate action to start the parity period

2022, June 13
08:00 a.m.
NOXXON enters into collaboration with US National Cancer Institute to characterize effects of lead compounds on brain tumors

2022, June 05
03:00 p.m.
NOXXON presents full top-line results from NOX-A12 Phase 1/2 GLORIA trial in glioblastoma at the 2022 ASCO Annual Meeting

2022, June 01
08:00 a.m.
NOXXON to host key opinion leader webinar on GLORIA study top-line results of NOX-A12 and radiotherapy combination in first-line glioblastoma

2022, May 30
08:00 a.m.
NOXXON announces convocation of the 2022 annual general meeting of shareholders

2022, May 26
11:00 p.m.
NOXXON announces presentation of NOX-A12 Phase 1/2 data in glioblastoma at the 2022 ASCO Annual Meeting and invitation to a dedicated KOL event

2022, May 19
08:00 a.m.
NOXXON amends equity-linked facility with Atlas

2022, May 16
06:00 p.m.
NOXXON announces results of the extraordinary general meeting of shareholders

2022, May 11
08:00 a.m.
NOXXON appoints leading brain cancer experts to scientific advisory board

2022, April 22
06:00 p.m.
NOXXON reports 2021 financial results

2022, April 21
06:00 p.m.
NOXXON announces €2.375 million financing under agreement with Atlas

2022, April 14
06:00 p.m.
NOXXON announces convocation of an Extraordinary General Meeting of shareholders

2022, April 06
08:00 a.m.
Top-line results from NOXXONs NOX-A12 Phase 1/2 GLORIA trial in brain cancer to be presented during 2022 ASCO Annual Meeting

2022, March 24
08:00 a.m.
NOXXON announces top-line data of Phase 1/2 GLORIA study with NOX-A12 in partially resected or biopsy-only MGMT-unmethylated newly-diagnosed glioblastoma patients

2022, February 10
08:00 a.m.
NOXXON to participate in partnering and investor conferences in February and March 2022

2022, January 28
06:00 p.m.
NOXXON announces €2.375 million financing under agreement with Atlas

2022, January 26
06:00 p.m.
Half-yearly report on the liquidity contract with Invest Securities

2022, January 07
08:00 a.m.
NOXXON provides progress update on the expansion arms of the Phase 1/2 GLORIA trial with NOX-A12 in brain cancer patients

2022, January 05
07:30 p.m.
NOXXON provides update on evaluation of NOX-A12 in non-oncology indication by a leading international pharma company

2022, January 03
06:00 p.m.
Corrected press release: NOXXON secures €17 million expansion of equity-linked facility with Atlas to advance NOX-A12 in glioblastoma and pancreatic cancer programs

2021, December 29
06:00 p.m.
NOXXON secures Euro 17 million expansion of equity-linked facility with Atlas to advance NOX-A12 in glioblastoma and pancreatic cancer programs

2021, December 15
06:00 p.m.
NOXXON announces results of the extraordinary general meeting of shareholders

2021, December 15
08:00 a.m.
NOXXON to participate in banking and investor conferences in January and February 2022

2021, December 07
08:00 a.m.
NOXXON announces enrolment of first patient in the expansion of the NOX-A12 Phase 1/2 trial in brain cancer

2021, December 02
08:00 a.m.
NOXXON summarizes essential points from Key Opinion Leader event on NOX-A12 & radiotherapy combination in brain cancer held on November 23, 2021 with Dr Frank A. Giordano

2021, November 22
08:00 a.m.
NOXXON: New Phase 1/2 data on NOX-A12 & radiotherapy combination in brain cancer presented at the Society for Neuro-Oncology Annual Meeting 2021

2021, November 16
08:00 a.m.
NOXXON to host Key Opinion Leader webinar on NOX-A12 and radiotherapy combination: a differentiated and promising new approach to treating brain cancer

2021, November 15
08:00 a.m.
NOXXON announces convocation of an Extraordinary General Meeting of shareholders

2021, November 12
08:00 a.m.
New positive interim results from NOXXON’s Phase 1/2 GLORIA trial in brain cancer to be presented at the Society for Neuro-Oncology Annual Meeting 2021

2021, November 09
08:00 a.m.
NOXXON to present at the third edition of Investir Day on November 23 in Paris, France

2021, November 03
08:00 a.m.
NOXXON provides update on timing for upcoming trials of NOX-A12 in pancreatic and brain cancer

2021, October 27
08:00 a.m.
Experienced financial executive, Bryan Jennings, joins NOXXON as CFO

2021, October 22
08:00 p.m.
NOXXON reports H1 2021 financial results and provides business update

2021, October 19
08:00 a.m.
NOXXON announces planned expansion of Phase 1/2 NOX-A12 brain cancer trial

2021, October 06
08:00 a.m.
NOXXON Pharma announces upcoming oral presentation at the Society for Neuro-Oncology Annual Meeting 2021

2021, September 29
08:00 a.m.
NOXXON to participate in biotech and health-tech conferences in October 2021

2021, September 22
08:00 a.m.
NOXXON enrolls last brain cancer patient in dose escalation portion of GLORIA study and confirms phase 1/2 read-out in Q1 2022

2021, August 25
08:00 a.m.
NOXXON to attend the German Fall conference on September 6 & 7, 2021

2021, August 05
08:00 a.m.
NOXXON provides update on NOX-A12 clinical programs

2021, July 28
08:00 a.m.
Half-yearly report on the liquidity contract with Invest Securities

2021, July 21
06:00 p.m.
NOXXON Pharma enters second clinical collaboration with MSD to evaluate NOX-A12 in combination with KEYTRUDA (pembrolizumab) in upcoming Phase 2 pancreatic cancer study

2021, June 24
07:00 p.m.
NOXXON announces appointments of Susan Coles, Martine van Vugt and Gregory Weaver to supervisory board and provides results of its 2021 annual general shareholders meeting

2021, June 08
08:00 a.m.
CORRECTED PRESS RELEASE: NOXXON announces positive results from second cohort in Phase 1/2 NOX-A12 brain cancer trial

2021, June 01
06:00 p.m.
NOXXON announces manufacturing of NOX-A12 drug substance for future clinical trials and issuance of convertible bonds under financing agreement with Atlas

2021, June 01
08:00 a.m.
NOXXON announces positive results from second cohort in Phase 1/2 NOX-A12 brain cancer trial

2021, May 25
08:00 a.m.
NOXXON announces convocation of its hybrid 2021 annual general meeting of shareholders

2021, May 12
06:00 p.m.
NOXXON announces participation in 7th Annual Immuno-oncology Innovation Forum, May 18-20, 2021

2021, May 10
06:00 p.m.
NOXXON announces Data Safety Monitoring Board validates NOX-A12 highest dose in Phase 1/2 brain cancer trial

2021, April 30
06:00 p.m.
NOXXON announces Euro 1.2M equity raise through conversion of warrants by Kreos Capital and other historical investors

2021, April 28
06:00 p.m.
NOXXON Pharma N.V. reports 2020 financial results

2021, April 14
06:00 p.m.
NOXXON successfully completes patient recruitment in Phase 1/2 brain cancer study of NOX-A12 plus radiotherapy

2021, March 12
08:00 a.m.
Data Safety Monitoring Board confirms safety and validates recruitment of last patients in final high-dose cohort of NOX-A12 in Phase 1/2 brain cancer study

2021, February 15
06:00 p.m.
NOXXON enrolls first patient in the high dose cohort of trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer

2021, February 08
06:00 p.m.
NOXXON appoints leading pancreatic cancer experts to Scientific Advisory Board

2021, February 01
06:00 p.m.
NOXXON appoints experienced cancer drug developer Dr. Jose Saro as chair of Scientific Advisory Board

2021, January 26
08:00 a.m.
NOXXON announces capital increase of Euro 6.4 million by private placement to further develop its business

2021, January 19
08:00 a.m.
Half-yearly report on the liquidity contract with Invest Securities

2020, December 29
08:00 p.m.
NOXXON announces initiation of NOX-A12 manufacturing for future clinical studies

2020, November 09
08:00 a.m.
NOXXON announces that Data Safety Monitoring Board validates further NOX-A12 dose escalation in Phase 1/2 brain cancer study

2020, October 29
08:00 a.m.
NOXXON publishes interim 2020 results

2020, October 28
08:00 a.m.
NOXXON announces completion of 6-month therapy for low-dose cohort in Phase 1/2 brain cancer study of NOX-A12 plus radiotherapy

2020, October 20
08:00 a.m.
NOXXON announces three additional clinical centers to recruit patients for NOX-A12 brain cancer trial

2020, October 14
07:00 p.m.
NOXXON secures expanded capacity and improved conversion conditions for convertible bonds from Atlas

2020, October 14
08:00 a.m.
NOXXON announces successful completion of patient recruitment for second dose cohort in phase 1/2 brain cancer study of NOX-A12 plus radiotherapy

2020, September 17
09:00 a.m.
NOXXON presents final clinical data from phase 1/2 NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the ESMO virtual congress 2020

2020, August 12
6:00 p.m.
NOXXON to present final clinical data from the NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the ESMO virtual congress 2020

2020, July 24
8:00 a.m.
NOXXON announces first brain cancer patient from second dose cohort reaches 4 weeks of treatment with NOX-A12 combined with radiotherapy

2020, July 13
6:00 p.m.
Half-yearly report on the liquidity contract with Invest Securities

2020, July 02
8:00 a.m.
NOXXON announces appointment of Oscar Izeboud to the supervisory board and provides results of the annual general shareholders meeting

2020, June 30
6:00 p.m.
NOXXON enrolls first patient in the second dose cohort of trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer

2020, June 16
6:00 p.m.
NOXXON announces capital increase of Euro 1.3 million by private placement to further develop its business

2020, June 12
6:00 p.m.
NOXXON announces issuance of tranches of Convertible Bonds under financing agreement with Atlas

2020, May 29
6:00 p.m.
NOXXON announces convocation of the hybrid annual general meeting of shareholders

2020, May 08
9:00 p.m.
NOXXON announces capital increase of EUR 5.5 million by private placement to further develop its business

2020, May 06
8:00 p.m.
NOXXON announces issuance of a tranche of Convertible Bonds under financing agreement with Atlas

2020, April 27
6:00 p.m.
NOXXON presents latest clinical data from the Phase 1/2 NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the AACR Virtual Annual Meeting 2020

2020, April 24
8:00 a.m.
NOXXON announces that Data Safety Monitoring Board validates NOX-A12 dose escalation in Phase 1/2 brain cancer study

2020, April 23
8:00 a.m.
NOXXON secures financing of up to 14.2 million Euro through convertible bonds from Atlas

2020, April 22
8:00 a.m.
NOXXON Pharma N.V. reports 2019 financial results

2020, April 20
7:00 p.m.
NOXXON announces complete conversion of Acuitas warrants

2020, April 14
6:00 p.m.
NOXXON to present latest clinical data from the NOX-A12 / KEYTRUDA combination trial in colorectal and pancreatic cancer at the AACR Virtual Annual Meeting 2020

2020, April 02
8:00 a.m.
NOXXON announces completion of patient recruitment for the first dose cohort in the phase 1/2 brain cancer study of NOX-A12 plus radiotherapy

2020, March 31
6:00 p.m.
NOXXON provides update on clinical trial recruitment and corporate operations during COVID-19 pandemic

2020, January 20
6:00 p.m.
NOXXON announces another capital increase of 0.5 million Euro through a private placement of shares

2020, January 16
6:00 p.m.
Half-yearly report on the liquidity contract with Invest Securities

2020, January 14
8:00 a.m.
NOXXON announces a capital increase of 0.5 million Euro through a private placement of shares

2019, December 20
8:00 a.m.
NOXXON announces first brain cancer patient reaches 10 weeks of treatment with NOX-A12 plus radiotherapy

2019, October 24
6:00 p.m.
NOXXON publishes interim 2019 results

2019, October 16
8:00 a.m.
NOXXON enrolls first patient in the phase 1/2 clinical trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer

2019, September 29
12:00 p.m.
NOXXON presents latest clinical data from Phase 1/2 NOX-A12 / Keytruda combination trial at the ESMO congress

2019, September 18
8:00 a.m.
NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the ESMO congress

2019, September 12
6:00 p.m.
NOXXON initiates patient recruitment for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of brain cancer patients

2019, August 15
8:00 a.m.
NOXXON announces completion of EUR 1 million capital increase

2019, August 06
8:00 p.m.
NOXXON announces a capital increase of Euro 1 million through a private placement of shares without warrants

2019, July 22
8:00 p.m.
Half-yearly report on the liquidity contract with Invest Securities

2019, July 19
8:30 p.m.
NOXXON raises amount of Euro 521 K in its rights issue

2019, June 27
8:00 a.m.
Results of NOXXON annual general shareholders meeting

2019, June 26
8:00 a.m.
NOXXON announces launch of capital increase right issue for an amount of up to Euro 3.9 M

2019, June 24
8:00 a.m.
NOXXON announces leading international pharma to evaluate NOX-A12 in new indication

2019, May 24
6:00 p.m.
NOXXON announces convocation of the annual general meeting of shareholders

2019, May 03
8:00 p.m.
NOXXON announces change within supervisory board

2019, April 12
7:00 p.m.
NOXXON Pharma N.V. reports 2018 financial results

2019, April 01
7:00 p.m.
NOXXON presents updated results from Phase 1/2 NOX-A12 / Keytruda combination trial at AACR 2019

2019, February 28
7:00 p.m.
NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the 2019 AACR Annual Meeting

2019, February 27
6:00 p.m.
NOXXON files application for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of brain cancer

2019, February 18
8:00 a.m.
NOXXON publishes a shareholder letter

2019, February 01
8:00 a.m.
New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer

2019, January 14
6:00 p.m.
Half-yearly report on the liquidity contract with Invest Securities

2019, January 04
8:00 a.m.
Results of NOXXON's extra-ordinary general meeting of shareholders

2018, December 20
8:00 a.m.
NOXXON announces participation in the East/West CEO Forum in San Francisco, in January 2019

2018, December 14
12:30 p.m.
NOXXON announces key findings that NOX-A12 plus Keytruda induces an immune response and results in clinical benefit for patients

2018, December 13
8:00 p.m.
NOXXON announces trading halt on Euronext Growth Paris ahead of trial data publication at the ESMO Immuno-Oncology Congress

2018, December 10
8:00 a.m.
NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at ESMO immuno-oncology congress on December 13-16, 2018

2018, December 03
0:01 a.m.
NOXXON announces convocation of an extra-ordinary general meeting of shareholders

2018, November 21
8:00 a.m.
NOXXON to launch NOX-A12 with radiotherapy clinical trial in patients with brain cancer

2018, November 16
8:00 a.m.
NOXXON announces EUR 6.2 million equity capital raise including US$ 5 million from US family office - Acuitas Capital, LLC

2018, October 26
8:00 a.m.
NOXXON to present top-line efficacy data from NOX-A12 / Keytruda combination trial in December as planned at ESMO Immuno-Oncology Conference

2018, October 23
6:00 p.m.
NOXXON to attend European investor and partnering conferences in November 2018

2018, October 16
8:00 a.m.
NOXXON to attend the ESMO 2018 congress in Munich

2018, October 11
8:00 a.m.
NOXXON publishes interim 2018 results

2018, October 02
6:00 p.m.
NOXXON presents top-line data from NOX-A12 monotherapy part of ongoing metastatic colorectal and pancreatic cancer trial

2018, September 19
6:00 p.m.
NOXXON announces listing of convertible bonds and additional investment

2018, September 19
8:00 a.m.
NOXXON to present clinical trial data at Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 'Translating Science into Survival'

2018, September 03
8:00 a.m.
NOXXON announces completion of patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer trial

2018, August 14
8:00 a.m.
NOXXON raises additional funds via ODIRNANE bonds and extends timing to cancel investor's unilateral right to invest

2018, August 08
6:00 p.m.
NOXXON to host Key Opinion Leader event on novel treatment approaches for glioblastoma on September 4th, 2018

2018, August 01
8:00 a.m.
NOXXON announces that it has secured additional financing

2018, July 16
6:00 p.m.
NOXXON announces amendment to loan agreements

2018, July 13
6:00 p.m.
Half-yearly report on the liquidity contract with invest securities

2018, July 03
8:00 a.m.
NOXXON issues tranche of ODIRNANE bonds

2018, June 28
8:00 p.m.
NOXXON provides update on patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer trial

2018, June 22
8:00 a.m.
Results of NOXXON annual general shareholders meeting

2018, June 15
8:00 a.m.
NOXXON announces that it has secured additional financing

2018, June 06
6:00 p.m.
NOXXON issues seventh tranche of ODIRNANE bonds

2018, May 29
8:00 a.m.
NOXXON provides clinical update prior to American Society of Clinical Oncology (ASCO) annual conference

2018, May 18
6:00 p.m.
NOXXON announces convocation of the annual general meeting of shareholders

2018, May 15
6:00 p.m.
NOXXON to present clinical trial update at BioEquity Europe

2018, April 30
9:00 p.m.
NOXXON PHARMA N.V. reports 2017 financial results

2018, April 26
8:00 a.m.
NOXXON publishes results of extraordinary shareholders meeting

2018, April 10
8:00 a.m.
NOXXON announces initiation of analyst coverage by Aurgalys

2018, March 22
9:00 p.m.
NOXXON announces convocation of an extra-ordinary general meeting of shareholders

2018, March 13
8:00 a.m.
NOXXON renegotiates ODIRNANE BSA financing agreement to remove unilateral option for investor to subscribe for tranches and to cancel existing warrents

2018, January 31
6.00 p.m.
Half-yearly report on the liquidity contract with Invest Securities

2018, January 23
8:00 a.m.
NOXXON issues fourth tranche of ODIRNANE bonds

2017, November 22NOXXON announces its participation in three European investor conferences in November and December 2017

2017, November 21NOXXON issues third tranche of ODIRNANE bonds

2017, October 30NOXXON releases interim 2017 results

2017, October 11NOXXON Pharma réaffirme son éligibilité au PEA-PME pour 2017/2018 (French only)

2017, October 03NOXXON Publishes Preclinical Proof-Of-Concept Data for Lead Compound NOX-A12 in Combination with Checkpoint Inhibitors

2017, September 29NOXXON Supervisory Board elects experienced US and EU biotech veteran Don deBethizy chairman

2017, September 28NOXXON provides update on ongoing phase 1/2 clinical trial with lead program NOX-A12

2017, September 26NOXXON announces its participation in two french investor conferences in October 2017

2017, September 19NOXXON issues second tranche of ODIRNANE bonds

2017, August 25Half-yearly report on the liquidity contract with Invest Securities

2017, July 18NOXXON issues first tranche of ODIRNANE bonds

2017, July 11NOXXON Pharma announces prospectus publication and share transfer to the public offering compartment of the EuroNext Growth market

2017, July 04NOXXON announces first patients treated in phase I/II clinical trial of NOX-A12 combined with Keytruda in metastatic pancreatic and colorectal cancer

2017, June 29Results of NOXXON Annual General Meeting

2017, June 07NOXXON publishes Annual General Meeting Documents

2017, May 26NOXXON announces record date and date of annual general meeting

2017, May 16NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12/Keytruda phase 1/2 combination trial

2017, May 02NOXXON PHARMA SECURES A PRIVATE PLACEMENT OF EUR 1 MILLION AND ADDITIONAL FINANCING OF UP TO EUR 10 MILLION THROUGH CONVERTIBLE NOTES WITH SHARE SUBSCRIPTION WARRANTS ATTACHED TO FINANCE FURTHER CLINICAL DEVELOPMENT OF NOX-A12

2017, April 30NOXXON Pharma N.V. reports 2016 financial results and announces advanced discussions regarding a convertible bond financing

2017, February 10NOXXON Pharma announces experienced industry cancer clinician Dr. Jarl Ulf Jungnelius to serve as NOXXON CMO

2017, January 06Half-yearly report on the liquidity contract with INVEST securities

2017, January 04NOXXON PHARMA licenses and assigns preclinical Spiegelmer programs to APTARION

2016, December 15NOXXON Pharma signs clinical immuno-oncology collaboration agreement with MSD to study NOX-A12 combined with Keytruda (pembrolizumab) in pancreatic and colorectal cancer

2016, December 05NOXXON Pharma announces new preclinical data showing synergy of lead compound NOX-A12 with natural killer (NK) Cell mediated therapies

2016, October 31NOXXON releases its interim 2016 results

2016, October 24NOXXON Pharma announces the implementation of a liquidity contract with invest securities

2016, October 10NOXXON Pharma demonstrates synergies between NOX-A12 and therapies working through T cells or NK cells

2016, September 28NOXXON Pharma NV lists its shares on Alternext Paris

2016, January 20NOXXON Pharma hosts key opinion leader symposium

2015, July 14NOXXON appoints Aram Mangasarian as CEO

2015, May 29First Data from NOXXONs NOX-H94 (Lexaptepid Pegol) Clinical Trial in ESA-Hyporesponsive Dialysis Patients Reported at ERA-EDTA Conference

2015, April 23Nature Communications Publications on the First X-ray Crystal Structures of Spiegelmers Bound to Protein Targets

2014, December 10New Addition to NOXXON Supervisory Board Brings Significant US Public Market Expertise

2014, December 05Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference

2014, September 26Cell Reports Publication on the Mechanism of Action of NOXXONs Anti-SDF-1 Spiegelmer Olaptesed Pegol (NOX-A12) in Preclinical Multiple Myeloma Models

2014, September 23NOXXON Spiegelmer receives FDA Orphan Drug Designation for Glioblastoma Treatment

2014, September 18NOXXON Pharma Expands Management Team by Appointing Don Munoz as Chief Financial Officer

2014, September 04Two Presentations at International Conferences of Preclinical Data on NOXXON's anti-C5a Spiegelmer, a Potential Drug in Pneumococcal Pneumonia-Induced Sepsis

2014, July 31NOXXON Initiates Phase IIa Study of Anti-Hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94) in Dialysis Patients with EPO-hyporesponsive Anemia

2014, June 13NOXXON presents Updates on Phase II Studies with Olaptesed Pegol (NOX-A12) in CLL and MM and Lexaptepid Pegol (NOX H94) in Anemic Cancer Patients

2014, June 02NOXXONs Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference

2014, April 08Anti-Hepcidin Spiegelmer Lexaptepid Pegol Increases Hemoglobin in Subset of Anemic Patients in Pilot Phase IIa Study

2014, April 04NOXXON presents Positive Results from Emapticap Pegol Phase IIa Diabetic Nephropathy Study

2013, December 09NOXXON presenting at ASH 2013

2013, July 24NOXXON Pharma Completes Patient Recruitment for Phase IIa Study in Diabetic Nephropathy

2012, December 04NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer NOX-H94

2012, September 26NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 in Second Oncology Indication: Multiple Myeloma

2012, July 11NOXXON Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 for Treatment of Chronic Lymphocytic Leukemia

2012, June 19NOXXON Initiates Phase IIa of Spiegelmer NOX-E36 for Treatment of Diabetic Nephropathy

2012, April 4NOXXONs NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model

2012, January 6NOXXON to Present at 30th Annual J.P. Morgan Healthcare Conference

2011, December 12NOXXONs SDF-1 inhibitor NOX-A12 completes Phase I

2011, September 06NOXXON initiates Phase I of NOX-H94 for Anemia of Chronic Disease

2011, February 03NOXXON Expands Management Team

2010, October 12NOXXON Confirms Total Capital Raise of €35m

2010, September 22NOXXON initiates multiple dose phase I clinical trial of SDF-1 inhibitor NOX-A12

2010, July 7NOXXON to initiate phase Ib clinical trial of MCP-1 inhibitor NOX-E36

2010, June 28NOXXON Pharma AG announces management changes

2010, May 27NOXXON Pharma AG raises €33 million in Series D Round

2010, May 18NOXXON Pharma AG appoints Dr. Aram Mangasarian as Chief Business Officer

2010, May 3NOXXON Announces the Completion of the First-in-Human Clinical Trial with Spiegelmer NOX-A 12

2009, December 3NOXXON Pharma AG Achieves Milestone in Partnership with Eli Lilly and Company

2009, November 2NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer NOX-A12

2009, October 12NOXXON announces excellent preliminary phase I trial results for Spiegelmer NOX-E36

2009, September 3NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer NOX-A12

2009, June 8NOXXON Announces Initiation of First Clinical Trial with a Spiegelmer

2008, July 8NOXXON Pharma announces appointment of Lawrence E. Posner to its Board of Directors

2008, June 11NOXXON Pharma AG Announces Licensing and Discovery Collaboration with Eli Lilly ...

2008, April 7NOXXON Receives Research Grant from the Federal Ministry of Education and Research

2008, January 7NOXXON Pharma AG appoints Dr. Frank Morich as CEO

2007, November 9NOXXON announces alliance with Roche

2007, June 8NOXXON Pharma announces appointment of Dr. Walter Wenninger as Chairman of the Board

2007, May 3NOXXON Pharma closes Series C Round at Euro 37 million

2007, February 9NOXXON Pharma AG to present at Bio CEO & Investor Conference 2007 in New York

2006, November 3NOXXON Pharma AG to present at Bio-Europe in Duesseldorf, Germany

2006, November 3NOXXON Pharma AG to present at Rodman & Renshaw 8th Annual Healthcare Conference

2006, October 4NOXXON Pharma AG to present at Sachs Associates 6th Annual Biotech in Europe...

2006, May 12NOXXON Pharma AG to present at the Rodman & Renshaw 3rd Annual Global Healthcare...

2006, May 10Change of management at NOXXON Pharma AG

2006, March 23NOXXON Pharma AG announces global strategic alliance with Pfizer. NOX-B11...

2006, March 15NOXXON Pharma AG announces publication of positive animal data with its vasopressin

2006, March 13NOXXON Pharma AG to present at Sachs Associates’ 5th Annual North America Forum...

2006, February 13NOXXON Pharma AG to present at Bio CEO & Investor Conference 2006 in New York

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (Google Analytics cookies). You can decide for yourself whether you want to accept the cookies. Please note that if you refuse cookies, you may no longer be able to use all of the site's functions.